Caas Capital Management LP Denali Therapeutics Inc. Transaction History

Caas Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $11.7 Million - $18.3 Million	-232,796 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $2.82 Million - $4.27 Million	52,333 Added 29.0%	232,796 $13.3 Million
Q4 2020 Feb 12, 2021	SELL	$36.89 - $93.56 $32.4 Million - $82.1 Million	-877,908 Reduced 82.95%	180,463 $15.1 Million
Q3 2020 Nov 09, 2020	SELL	$23.13 - $38.84 $11.5 Million - $19.4 Million	-498,537 Reduced 32.02%	1,058,371 $37.9 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $8.4 Million - $15.1 Million	524,881 Added 50.86%	1,556,908 $37.6 Million
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $14.7 Million - $28.9 Million	1,032,027 New	1,032,027 $18.1 Million

240

121M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.01B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.